AbbVie

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
Motley Fool
AbbVie
Boehringer Ingelheim
Skyrizi
Novartis
Cosentyx
psoriasis
Flag link:
AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required
AbbVie nears Allergan lockup with EU antitrust approval—and only one selloff required
Fierce Pharma
AbbVie
Allergan
antitrust
M&A
brazikumab
Europe
Flag link:
A big finish confirms 2019 as a takeover year to remember
A big finish confirms 2019 as a takeover year to remember
EP Vantage
M&A
AbbVie
Allergan
Astellas
Bristol-Myers Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Flag link:
AbbVie answers Allergan aesthetics worries with separate new unit
AbbVie answers Allergan aesthetics worries with separate new unit
Fierce Pharma
AbbVie
Allergan
aesthetics
M&A
Allergan Aesthetics
Flag link:
Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says
Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says
Fierce Pharma
AbbVie
Allergan
M&A
Humira
Botox
Flag link:
In last-minute deal, Allergan forks over a hefty $300M to settle pay-for-delay dispute
In last-minute deal, Allergan forks over a hefty $300M to settle pay-for-delay dispute
Fierce Pharma
AbbVie
Allergan
M&A
pay-for-delay
Warner Chilcott
Watson Pharmaceuticals
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020
Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020
Fierce Pharma
drug pricing
Pfizer
Bristol-Myers Squibb
AbbVie
Flag link:
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Fierce Pharma
drug ads
television ads
Roche
Ocrevus
GSK
Dovato
AbbVie
Humira
Flag link:
After big M&A year, will pharma move away from massive deals in 2020?
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Flag link:
Leukemia rivals try to stay ahead as Merck, Lilly chase
Leukemia rivals try to stay ahead as Merck, Lilly chase
Biopharma Dive
Merck
Eli Lilly
AbbVie
JNJ
Imbruvica
ARQ 531
LOXO-305
CLL
ASH2019
Flag link:
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
BioSpace
AbbVie
Scripps Research Institute
cancer
immunology
fibrosis
Flag link:
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
Pharmaforum
AstraZeneca
cancer
Calquence
ASH2019
Imbruvica
JNJ
AbbVie
CLL
Flag link:
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL
Fierce Pharma
AbbVie
Roche
CLL
ASH2019
Venclexta
Flag link:
UCB posts more supportive data from Humira rival bimekizumab
UCB posts more supportive data from Humira rival bimekizumab
Pharmaforum
UCB Pharma
bimekizumab
AbbVie
Humira
psoriasis
biosimilars
Flag link:
Pro-AbbVie bias may be driving rheumatologist confidence in newcomer Rinvoq: analyst
Pro-AbbVie bias may be driving rheumatologist confidence in newcomer Rinvoq: analyst
Fierce Pharma
AbbVie
Rinvoq
Flag link:
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
Pharmaforum
ICER
AbbVie
Rinvoq
rheumatoid arthritis
biosimilars
Flag link:
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst
AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst
Fierce Pharma
AbbVie
Skyrizi
Rinvoq
Allergan
drug launches
Flag link:
Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
Motley Fool
Enanta Pharmaceuticals
earnings
AbbVie
Mavyret
hepatitis C
Flag link:
AbbVie Shareholders Have a Lot to Look Forward To With Allergan
AbbVie Shareholders Have a Lot to Look Forward To With Allergan
Motley Fool
AbbVie
Allergan
earnings
M&A
Flag link:

Pages